Echo IQ

ASX: EIQ RELEASE **JULY 27, 2022**

Echo IQ announces new clinical study with world-leading US teaching hospital

Highlights:

- **Echo IQ enters study agreement with Beth Israel Deaconess Medical Center, a Harvard Medical School teaching hospital**
- **Study to evaluate Echo IQ AI algorithm in US clinical setting**

Sydney, Australia: AI and Medical Technology company Echo IQ (the Company) (ASX: EIQ) is pleased to announce that it will be collaborating with Beth Israel Deaconess Medical Center (BIDMC), the world-class teaching hospital of Harvard Medical School, on a clinical study of the Company's technology. The study, a retrospective clinical cohort and outcomes study, is being conducted to evaluate Echo IQ's artificial intelligence algorithm in detecting individuals with severe aortic stenosis and equivalent risk of mortality associated with an aortic stenosis phenotype in a North American cohort.

The Principal Investigator of the study is Jordan B. Strom, MD, MSc, FACC, FASE, Assistant Professor of Medicine at Harvard Medical School, Director of Echocardiographic Research, and Associate Director of the Echocardiography Laboratory at Beth Israel Deaconess Medical Center. He is a faculty investigator and Section Head for Cardiovascular Imaging Research at the Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology.

This study adds to those already in progress by the Company and is expected to augment an already-extensive body of research in this important space. Aortic stenosis is the most prevalent form of heart valve disease in high-income countries[1,2] and recent estimates from the UK[3] and Australia[4] indicate that its prevalence will increase in line with the progressive ageing of the population. Echo IQ is using the power of AI to support enhanced diagnosis of this condition, and other forms of structural heart disease.

Echo IQ Chief Medical Advisor Professor David Playford commented: *"Applying AI-backed algorithms to structural heart disease has the potential to unlock faster, more actionable diagnosis of conditions that are increasingly treatable. Reducing the burden of disease remains a core aim of medicine and we are looking forward to demonstrating the impact of Echo IQ's solutions in this important US study, in conjunction with the world-leading cardiology team at Beth Israel Deaconess Medical Center and Harvard Medical School."*

Echo IQ Executive Chair Andrew Grover said: *"This trial demonstrates another strong step towards US commercialisation of Echo IQ's solutions. The involvement of a teaching hospital of this calibre and reputation is testament to the importance of the work we are undertaking, and we look forward to sharing more news of our successes in the weeks ahead."*

- ENDS -

Authorised for release by the Board of Directors of Echo IQ Limited

[1] Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. *Lancet*. 2006;368(9540):1005-11.
[2] Durko AP, Osnabrugge RL, Van Mieghem NM, Milojevic M, Mylotte D, Nkomo VT, et al. Annual number of candidates for transcatheter aortic valve implantation per country: current estimates and future projections. *Eur Heart J*. 2018;39(28):2635-42.
[3] Strange GA, Stewart S, Curzen N, et al. Uncovering the treatable burden of severe aortic stenosis in the UK. *Open Heart* 2022; **9**(1).
[4] Strange G, Scalia GM, Playford D, Stewart S. Uncovering the treatable burden of severe aortic stenosis in Australia: current and future projections with an ageing population. BMC Health Services Research. 2021.21;790.

Echo IQ

Media Enquiries:
Philip Woolff, Chief Operating Officer
philip.woolff@echoiq.ai / marketing@echoiq.ai / +61 (0)490 030 620

Investor Enquiries:
Andrew Grover, Executive Chair
Andrew.grover@echoiq.ai / investors@echoiq.ai

ABOUT ECHO IQ
Echo IQ uses AI-driven technology and proprietary software to improve decision making in Cardiology. The company is based in Sydney, Australia.